AN2 Therapeutics IncNASDAQ:ANTX
- LAST PRICE12.3100
- TODAY'S CHANGE (%)1.8300 (17.4618%)
- Bid / Lots11.0100/ 1
- Ask / Lots17.6100/ 2
- Open / Previous Close10.3000 / 10.4800
- Day Range
- 52 Week Range
- Volume19,868
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANTX |
|---|---|---|
| 10:02 ET | 200 | 10.51 |
| 10:04 ET | 721 | 10.66 |
| 10:06 ET | 1110 | 10.6735 |
| 10:18 ET | 204 | 10.55 |
| 10:56 ET | 100 | 10.645 |
| 10:58 ET | 1000 | 10.645 |
| 12:10 ET | 866 | 11 |
| 12:42 ET | 100 | 10.995 |
| 01:42 ET | 2333 | 11.04 |
| 01:47 ET | 999 | 10.9359 |
| 01:49 ET | 100 | 11.29 |
| 01:58 ET | 100 | 11.33 |
| 02:27 ET | 100 | 11.33 |
| 02:56 ET | 100 | 11.42 |
| 03:21 ET | 100 | 11.5 |
| 03:33 ET | 100 | 11.45 |
| 03:39 ET | 1375 | 11.49 |
| 03:44 ET | 1148 | 11.81 |
| 03:48 ET | 100 | 11.72 |
| 03:51 ET | 100 | 12.195 |
| 03:53 ET | 100 | 12.2 |
| 03:55 ET | 1196 | 11.97 |
| 03:57 ET | 157 | 12.03 |
| 04:00 ET | 896 | 12.31 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AN2 Therapeutics Inc | 203.3M | 0.0x | --- |
Olema Pharmaceuticals Inc | 200.7M | -1.9x | --- |
Tenaya Therapeutics Inc | 207.3M | -1.1x | --- |
AC Immune SA | 195.5M | -2.5x | --- |
Singular Genomics Systems Inc | 194.2M | -2.2x | --- |
Gossamer Bio Inc | 216.4M | -0.8x | --- |
Company Information
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic and progressive infectious disease caused by bacteria, mycobacteria. Epetraborole has antimycobacterial activity through the inhibition of an essential and universal step in bacterial protein synthesis. Its mechanism of action is enabled by boron chemistry, which is the Company’s core technology approach. Epetraborole is under development in a pivotal Phase II/III clinical trial as a once-daily, oral treatment for patients with NTM lung disease with an initial focus on treatment-refractory Mycobacterium avium complex (MAC) lung disease.
Contact Information
- Headquarters
- 1800 El Camino Real, Suite DMENLO PARK, CA, United States 94025-3069
- Phone
- 650-331-9090
- Fax
- ---
Executives
- Chairman of the Board, Co-Founder
- Joseph Zakrzewski
- President, Chief Executive Officer, Co-Founder, Director
- Eric Easom
- Co-Founder, Head of Biology
- Michael Alley
- Chief Financial Officer, Treasurer, Secretary
- Lucy Day
- Chief Development Officer
- Sanjay Chanda
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.3M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 19.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $3.30 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
